Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous Immunoglobulins in MS.

M Stangel1, R Gold

  • 1Department of Neurology, Medizinische Hochschule Hannover, OE 7210, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Stangel.Martin@MH-Hannover.de

International MS Journal
|June 16, 2005
PubMed
Summary

High-dose intravenous immunoglobulins (IVIg) show benefits for relapsing-remitting multiple sclerosis (MS) but not progressive MS. IVIg is a potential second-line treatment for MS when other therapies fail.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid differentiation of MOGAD and MS after a single optic neuritis.

Journal of neurology·2024
Same author

Characteristic retinal atrophy pattern allows differentiation between pediatric MOGAD and MS after a single optic neuritis episode.

Journal of neurology·2022
Same author

Bilateral giant cell arteritis with skin necrosis following SARS-CoV-2 vaccination.

The British journal of dermatology·2021
Same author

A rare case of neuro- and otosyphilis in secondary syphilis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

S1 guidelines "lumbar puncture and cerebrospinal fluid analysis" (abridged and translated version).

Neurological research and practice·2020
Same author

Pathological spontaneous activity as a prognostic marker in chronic inflammatory demyelinating polyneuropathy.

European journal of neurology·2020

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Autoimmune disorders, including multiple sclerosis (MS), involve complex immune mechanisms.
  • High-dose intravenous immunoglobulins (IVIg) are emerging as a treatment for neurological autoimmune diseases.

Purpose of the Study:

  • To evaluate the efficacy of IVIg in different courses and stages of multiple sclerosis (MS).
  • To determine the therapeutic potential of IVIg in autoimmune neurological conditions.

Main Methods:

  • Clinical trials were conducted to assess IVIg effects across various MS disease courses.
  • In vivo and in vitro studies explored IVIg's immunomodulatory mechanisms relevant to MS.

Main Results:

  • IVIg demonstrated beneficial effects in relapsing-remitting MS.
  • IVIg showed no significant effect in the secondary progressive phase of MS.
  • Clinical trials did not confirm IVIg-induced remyelination in humans, despite animal study data.

Conclusions:

  • IVIg is considered a second-line therapy for relapsing-remitting MS, particularly when first-line treatments are not tolerated.
  • Current evidence does not support IVIg for progressive MS or as a remyelinating agent in humans.

Related Experiment Videos